Theophylline
theophylline anhydrous — Theo-24, Elixophyllin, Theolair
Indications
| Indication | Approved Population | Therapy Type | Status |
|---|---|---|---|
| Chronic asthma — symptom control and reversible airflow obstruction | Adults and children (all ages, with age-appropriate dosing) | Add-on controller or alternative bronchodilator | FDA Approved |
| COPD — chronic symptoms, dyspnoea, and air trapping | Adults | Add-on bronchodilator (second/third-line) | FDA Approved |
Theophylline occupies a diminished but still relevant role in chronic airway disease management. Current GINA and GOLD guidelines position it as a second- or third-line add-on therapy when first-line agents (inhaled corticosteroids, long-acting beta-agonists, long-acting muscarinic antagonists) provide insufficient control. Its narrow therapeutic window and extensive drug interaction profile demand careful patient selection. In chronic asthma, theophylline reduces exacerbation frequency, nocturnal symptoms, and rescue beta-agonist use. In COPD, it modestly improves dyspnoea and diaphragmatic contractility with minimal spirometric improvement.
Apnoea of prematurity — Well-established neonatal use; loading dose 5 mg/kg followed by maintenance dosing by age and weight. Caffeine citrate has largely replaced theophylline for this indication. Evidence quality: High.
Acute severe asthma (IV aminophylline) — Loading dose 5–7 mg/kg IV over 20–30 min, followed by continuous infusion. Benefit beyond standard therapy is debated; the GINA guideline does not recommend routine use. Evidence quality: Moderate.
Bradycardia in premature neonates — Used when caffeine is unavailable. Evidence quality: Moderate.
Dosing
Oral Dosing — Titration by Age and Risk Category (based on FDA PI Table V)
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| Adults 16–60 yr, no risk factors for impaired clearance | 300 mg/day divided q6–8h (Days 1–3) | 400 mg/day divided q6–8h (Days 4–6); then 600 mg/day (Day 7+) | 600 mg/day | Titrate in 3-day steps; dose based on IBW Check serum level after final titration; target 10–15 mcg/mL |
| Children 6–15 yr, no risk factors | 12–14 mg/kg/day max 300 mg/day; divided q4–6h | 16 mg/kg/day max 400 mg/day (Days 4–6) | 20 mg/kg/day (6–11 yr); 16 mg/kg/day (12–15 yr) max 600 mg/day (6–11 yr); max 400 mg/day (12–15 yr) | Use IBW; children have faster clearance and need higher mg/kg doses Monitor levels at 6-month intervals in growing children |
| Elderly >60 yr, or patients with risk factors for impaired clearance | 300 mg/day divided q6–8h (Days 1–3) | 400 mg/day | 400 mg/day | Do not exceed 400 mg/day unless level <10 mcg/mL and patient remains symptomatic Risk factors: CHF, liver disease, fever ≥102 °F for ≥24 h, cessation of smoking |
| Infants <1 yr (oral solution) | Total daily dose (mg) = [(0.2 × age in weeks) + 5.0] × body weight (kg) | Per formula | Divide into q6–8h doses; frequent level monitoring essential Neonatal metabolism immature; t½ mean ~30 h in premature neonates (range 17–43 h) | |
| Neonatal apnoea of prematurity | Loading: 5 mg/kg | <24 days: 1 mg/kg q12h; ≥24 days: 1.5 mg/kg q12h | Guided by serum level | Caffeine citrate is now preferred agent ~50% excreted unchanged renally in neonates; monitor renal function |
| Acute bronchospasm — IV loading (aminophylline equivalent) | 5–7 mg/kg IV over 20–30 min | 0.4–0.6 mg/kg/hr IV infusion | Guided by serum level max 900 mg/day in adults unless level requires more | Omit or halve loading dose if patient already on theophylline Each 1 mg/kg loading dose raises serum level ~2 mcg/mL |
Dose Adjustment by Serum Theophylline Level (based on FDA PI Table VI)
| Serum Level (mcg/mL) | Action | Notes |
|---|---|---|
| <9.9 | Increase dose by ~25% if symptomatic | Recheck level after 3 days at new dose |
| 10–14.9 | Maintain current dose if tolerated | Ideal therapeutic range; recheck in 6–12 months |
| 15–19.9 | Consider reducing dose by ~10% as precaution | Higher risk of adverse effects, especially in COPD with hypoxia |
| 20–24.9 | Decrease dose by ~25%; recheck in 3 days | Withhold next dose if symptomatic; resume at lower dose |
| 25–30 | Skip next dose; decrease total daily dose by ≥25% | Evaluate for signs of toxicity; recheck level in 3 days |
| >30 | Hold doses; treat toxicity per protocol | Consider activated charcoal, supportive care; haemodialysis if >100 (acute) or >60 (chronic) |
Tobacco smoking induces CYP1A2, increasing theophylline clearance by approximately 50% in young adults and up to 80% in elderly smokers. Even passive smoke exposure can increase clearance by up to 50%. When a patient stops smoking, clearance falls by approximately 40% within one week, often requiring a prompt dose reduction to prevent toxicity. Nicotine replacement therapy (gum/patch) does not affect theophylline clearance—it is the polycyclic aromatic hydrocarbons in smoke, not nicotine, that induce CYP1A2.
Pharmacology
Mechanism of Action
Theophylline exerts its therapeutic effects through multiple molecular mechanisms. The primary bronchodilatory action is mediated by non-selective inhibition of phosphodiesterase (PDE) isoenzymes, particularly PDE III and to a lesser extent PDE IV, which increases intracellular cyclic AMP and cyclic GMP concentrations in airway smooth muscle, promoting relaxation. At therapeutic concentrations, theophylline also antagonises adenosine A1 and A2 receptors, which contributes to bronchodilation but also underlies some adverse effects (central nervous system stimulation, cardiac arrhythmias). Additionally, theophylline enhances diaphragmatic contractility by facilitating calcium uptake through adenosine-mediated channels—a clinically meaningful effect in patients with COPD and respiratory muscle fatigue. At lower serum concentrations (5–10 mcg/mL), anti-inflammatory and immunomodulatory properties become relevant, including suppression of inflammatory cytokine release, reduction of eosinophil infiltration, and enhancement of histone deacetylase activity, which may restore corticosteroid sensitivity in COPD patients.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Rapid and complete from oral solution/IR forms; Tmax 1–2 h (IR), 6–13 h (ER); no appreciable first-pass effect; food does not affect IR absorption but may alter ER release profile | Extended-release tablets should be administered consistently with or without food to avoid fluctuations in bioavailability |
| Distribution | Vd ~0.45 L/kg (IBW); ~40% protein bound (albumin); distributes into body water but poorly into fat; crosses placenta, enters breast milk and CSF freely | Dose on ideal body weight in obese patients; reduced protein binding in cirrhosis, pregnancy, and elderly may increase free drug fraction—risk of toxicity at “normal” total levels |
| Metabolism | ~90% hepatic in adults; CYP1A2 (N-demethylation to 1-methylxanthine and 3-methylxanthine), CYP2E1/3A3 (hydroxylation to 1,3-dimethyluric acid); ~6% N-methylated to caffeine; non-linear (capacity-limited) kinetics | Non-linearity means disproportionate increases in serum level with small dose increases; limit dose changes to ~25% increments. CYP1A2 inducers (smoking, rifampicin) and inhibitors (ciprofloxacin, cimetidine) have major clinical impact |
| Elimination | ~10% excreted unchanged in urine (adults); remainder as metabolites: 1,3-dimethyluric acid (35–40%), 1-methyluric acid (20–25%), 3-methylxanthine (15–20%); t½ varies widely by age and clinical state (3–30+ h); neonates excrete ~50% unchanged renally | No dose adjustment needed for renal impairment in adults/children >3 months; neonates with renal impairment require dose reduction. Steady state reached in 30–65 h (mean 40 h) |
Side Effects
Theophylline adverse effects are uniquely concentration-dependent. The FDA PI does not provide a traditional incidence table but instead stratifies reactions by serum level. Caffeine-like effects occur in approximately 50% of patients when therapy is initiated at doses above recommended starting levels (>300 mg/day in adults, >12 mg/kg/day in children). With proper low-dose initiation and titration, these effects are largely avoidable.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Nausea | ~50% at improper initiation | Occurs when starting dose is too high; largely avoidable with slow titration per FDA Table V |
| Vomiting | ~50% at improper initiation | Persistent or repetitive vomiting is a warning sign of toxicity; check level immediately |
| Headache | Very common at initiation | Caffeine-like; typically transient over first 1–2 weeks of appropriate titration |
| Insomnia | Very common at initiation | Adenosine receptor antagonism-mediated; avoid evening dosing or consider extended-release formulations |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Diarrhoea | <10% at therapeutic levels | PDE inhibition in GI tract; dose-related |
| Irritability / restlessness | <10% | More prominent in children; may transiently affect school behaviour |
| Fine skeletal muscle tremor | <10% | Dose-related; consider level check if persistent |
| Transient diuresis | <10% | Adenosine receptor antagonism in kidney; usually mild |
| Tachycardia (sinus) | <10% | Related to catecholamine release; clinically relevant above 15 mcg/mL in at-risk patients |
| Gastro-oesophageal reflux / increased acid secretion | <10% | PDE-mediated relaxation of lower oesophageal sphincter; may worsen pre-existing GORD |
| Persistent caffeine-like effects during maintenance | <3% children; <10% adults | Even within therapeutic range (10–20 mcg/mL); may require dose reduction or drug discontinuation |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Seizures | Levels >20 mcg/mL; rare at <20 (elderly/neurological disease) | Minutes to hours after toxic level reached | Stop theophylline immediately; IV benzodiazepines; check level; consider haemodialysis for severe toxicity |
| Cardiac arrhythmias (ventricular tachycardia, SVT, atrial fibrillation) | Levels >20 mcg/mL; multifocal atrial tachycardia at ≥15 mcg/mL in COPD with hypoxia | Any time during supratherapeutic exposure | Stop theophylline; continuous cardiac monitoring; standard antiarrhythmic management; correct hypokalaemia |
| Intractable vomiting (toxicity marker) | Levels >20 mcg/mL | Often the earliest sign of serious toxicity | Withhold all theophylline; check level urgently; GI decontamination if recent ingestion |
| Hypotension / cardiovascular collapse | Severe toxicity (>40–60 mcg/mL chronic, >80–100 mcg/mL acute) | Hours after massive ingestion or accumulation | Aggressive fluid resuscitation; vasopressors; haemodialysis; ICU admission |
| Metabolic derangements (hypokalaemia, hyperglycaemia, metabolic acidosis) | Levels >20 mcg/mL | Concurrent with other toxicity features | Correct electrolytes aggressively; potassium replacement critical to reduce arrhythmia risk |
| Reason for Discontinuation | Incidence | Context |
|---|---|---|
| Persistent GI intolerance | Most common | Nausea, vomiting, GORD exacerbation despite dose adjustment |
| CNS effects (insomnia, anxiety, headache) | Common | Persistent at therapeutic levels in a minority; consider alternative controller |
| Cardiac effects (palpitations, tachycardia) | Uncommon | More relevant in patients with underlying cardiac disease |
Theophylline toxicity is a medical emergency. Serum levels above 20 mcg/mL require intervention; above 40 mcg/mL (chronic) or 100 mcg/mL (acute) may warrant extracorporeal removal (haemodialysis or haemoperfusion). Activated charcoal (single or multiple doses) is effective for GI decontamination. Seizures should be treated with IV benzodiazepines. Correct hypokalaemia aggressively to reduce arrhythmia risk. Whole-bowel irrigation may be considered for sustained-release ingestions.
Drug Interactions
Theophylline is primarily metabolised by CYP1A2, with minor contributions from CYP2E1 and CYP3A3. Its narrow therapeutic index makes even modest changes in clearance clinically dangerous. The FDA PI lists over 30 interacting drugs. The most clinically important interactions are presented below.
Monitoring
-
Serum Theophylline Level
At initiation, after dose changes, q6–12 months stable
Routine Draw peak level 12 h after evening dose or 9 h after morning dose at steady state. Target 10–15 mcg/mL. In acutely ill patients, check every 24 h. In rapidly growing children, check every 6 months. If unbound level needed (cirrhosis, pregnancy, elderly), target 6–12 mcg/mL. -
Heart Rate / ECG
Baseline; if symptoms of toxicity
Trigger-based Monitor for tachycardia and arrhythmias, especially in patients with pre-existing cardiac disease or COPD with hypoxia (multifocal atrial tachycardia may occur at levels ≥15 mcg/mL). -
Hepatic Function
Baseline; with intercurrent liver illness
Trigger-based Hepatic disease reduces theophylline clearance by 50% or more (cirrhosis t½ up to 32 h). Any new hepatic insult (acute hepatitis, decompensation) requires immediate dose reduction and level monitoring. -
Electrolytes (K+, Glucose)
If toxicity suspected
Trigger-based Theophylline toxicity causes hypokalaemia (beta-2 mediated intracellular shift), hyperglycaemia, and metabolic acidosis. Potassium correction is critical for arrhythmia prevention. -
Smoking Status
Every visit
Routine Starting or stopping tobacco or marijuana smoking dramatically alters theophylline clearance. A patient who quits smoking needs a dose reduction and level check within 1 week. -
Concomitant Medications
Every visit; any medication change
Routine Over 30 drugs interact with theophylline. A level check should accompany any addition or removal of an interacting drug, especially CYP1A2 inhibitors (ciprofloxacin, cimetidine, fluvoxamine) or inducers (rifampicin, phenytoin).
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to theophylline or any component of the formulation
Relative Contraindications (Specialist Input Recommended)
- Active peptic ulcer disease — theophylline increases gastric acid secretion and may worsen ulceration
- Seizure disorders — theophylline lowers seizure threshold; concurrent use requires extreme caution and close level monitoring
- Unstable cardiac arrhythmias (excluding bradyarrhythmias) — risk of tachyarrhythmia exacerbation
Use with Caution
- Hepatic insufficiency (cirrhosis, acute hepatitis, cholestasis) — clearance reduced ≥50%; require aggressive dose reduction and frequent level monitoring
- Congestive heart failure — clearance reduced ≥50% proportional to disease severity
- Elderly (>60 yr) — reduced clearance (~30%); max 400 mg/day unless level <10 mcg/mL; more sensitive to toxic effects
- Fever ≥39 °C (102 °F) sustained ≥24 h — reduced clearance; check levels and consider dose reduction
- Hypothyroidism — reduced clearance (t½ ~11.6 h); reverse with hyperthyroidism (t½ ~4.5 h)
- Neonates and infants <1 yr — immature metabolic pathways; greatly prolonged half-life
- Pregnancy (Category C) — teratogenic in animals at high doses; clearance may change across trimesters
- Breastfeeding — breast milk concentration approximates serum; infant may receive 10–20 mg/day
- Recent smoking cessation — clearance falls ~40% within 1 week; dose reduction essential
Theophylline has a narrow therapeutic window (10–20 mcg/mL) with non-linear pharmacokinetics. Small dose increases can produce disproportionately large rises in serum concentration. At levels above 20 mcg/mL, the frequency and severity of adverse effects escalate rapidly, including intractable seizures, life-threatening cardiac arrhythmias, and death. Serum theophylline monitoring is mandatory. Dose adjustments should be limited to approximately 25% increments, with level confirmation before further changes.
Patient Counselling
Purpose of Therapy
Theophylline is a long-term controller medicine that relaxes the muscles around airways and reduces inflammation, making breathing easier. It does not provide immediate relief during an acute asthma attack. A separate rescue inhaler must be kept on hand at all times.
How to Take
Take theophylline exactly as prescribed, at evenly spaced intervals. Do not crush or chew extended-release tablets. Consistency with food timing is important—always take your dose the same way (with or without food) to maintain steady drug levels. Never take a double dose if you miss one; take the next dose at its usual time. Regular blood tests to check drug levels are essential for safe use.
Sources
- Theophylline (anhydrous) extended-release tablets prescribing information. DailyMed / FDA. DailyMed Primary source for all dosing tables (Table V and VI), pharmacokinetic data (Table I), drug interactions (Table II), adverse reactions, and contraindications cited in this monograph.
- Theophylline in 5% Dextrose Injection prescribing information. FDA. FDA Label Intravenous formulation PI providing infusion rate guidance and IV-specific dosing parameters.
- Zyflo CR (zileuton) prescribing information. FDA. FDA Label Source for the zileuton–theophylline interaction data (clearance reduction ~50%, AUC doubling).
- Seddon P, Bara A, Ducharme FM, Lasserson TJ. Oral xanthines as maintenance treatment for asthma in children. Cochrane Database Syst Rev. 2006;(1):CD002885. doi:10.1002/14651858.CD002885.pub2 Cochrane review supporting theophylline efficacy in paediatric asthma while highlighting its inferior tolerability compared to inhaled corticosteroids.
- Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2002;(4):CD003902. doi:10.1002/14651858.CD003902 Cochrane review demonstrating modest improvement in FEV1 and symptoms in COPD patients treated with theophylline.
- Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. 2024 Update. ginasthma.org Positions theophylline as an alternative add-on therapy at Steps 2–4 when preferred controllers are unavailable or unaffordable.
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for Diagnosis, Management, and Prevention of COPD. 2024 Report. goldcopd.org Notes that theophylline is not recommended as a first-line treatment for COPD; use only when other long-acting bronchodilators are unavailable.
- Hendeles L, Massanari M, Weinberger M. Revised FDA labeling guideline for theophylline oral dosage forms. Pharmacotherapy. 1995;15(4):409–427. PubMed Landmark publication establishing the modern theophylline dosing titration schema (Table V) adopted by the FDA.
- Barnes PJ. Theophylline. Am J Respir Crit Care Med. 2013;188(8):901–906. doi:10.1164/rccm.201302-0388PP Authoritative review of theophylline’s molecular mechanisms including PDE inhibition, adenosine antagonism, and anti-inflammatory properties at low concentrations.
- Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ. Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med. 2004;200(5):689–695. doi:10.1084/jem.20040416 Demonstrates how low-dose theophylline enhances HDAC activity, potentially restoring corticosteroid sensitivity in COPD.
- Statpearls: Theophylline. Patel P, Ginter S. In: StatPearls [Internet]. Updated May 1, 2023. NCBI Bookshelf Clinical review covering pharmacokinetics across age groups, interaction profiles, and current place in therapy.
- Upton RA. Pharmacokinetic interactions between theophylline and other medication. Clin Pharmacokinet. 1991;20(1):66–80. doi:10.2165/00003088-199120010-00005 Comprehensive PK review of theophylline drug interactions with quantitative clearance change data.
- Shannon MW. Life-threatening events after theophylline overdose: a 10-year prospective analysis. Arch Intern Med. 1999;159(9):989–994. doi:10.1001/archinte.159.9.989 Prospective study characterising the relationship between serum theophylline levels and life-threatening events, informing toxicity management thresholds.